Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, today announced that in November, the first patient was dosed in its Phase 1 clinical trial of VIPER-101. VIPER-101 is an enabled autologous cell therapy designed to treat relapsed and/or refractory (r/r) T cell lymphoma, a severe disease with limited treatment options.
VIPER-101 incorporates Vittoria’s proprietary Senza5™ platform which integrates CD5 gene-editing technology with a rapid, 5-day manufacturing process to deliver a potent and targeted therapy for r/r T cell lymphoma. This innovative approach is intended to enhance the efficacy and safety profile of conventional autologous cell therapies, offering new hope to patients whose cancers have not responded to traditional lines of treatment.